The recent arrival of CDK4/6 inhibitor agents, with an approximate doubling of progression-free
survival (PFS) associated with their use in hormone receptor-positive, HER2-negative …

An increasingly recognized resistance mechanism to androgen receptor (AR)-directed therapy
in prostate cancer involves epithelial plasticity, in which tumor cells demonstrate low to …

The emergence of next-generation sequencing (NGS) platforms imposes increasing demands
on statistical methods and bioinformatic tools for the analysis and the management of the …

Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent
through several comprehensive profiling efforts, but little is known about the impact of this …

Some cancers evade targeted therapies through a mechanism known as lineage plasticity,
whereby tumor cells acquire phenotypic characteristics of a cell lineage whose survival no …

The transition from castration-resistant prostate adenocarcinoma (CRPC) to neuroendocrine
prostate cancer (NEPC) has emerged as an important mechanism of treatment resistance. …

Randomized clinical trials demonstrated that CDK4/6 inhibitors are highly effective in patients
with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer in …

A major hurdle in the study of rare tumors is a lack of existing preclinical models. Neuroendocrine
prostate cancer is an uncommon and aggressive histologic variant of prostate cancer …

Abstract We developed a novel software tool, EXCAVATOR, for the detection of copy number
variants (CNVs) from whole-exome sequencing data. EXCAVATOR combines a three-step …

Motivation: The discovery of novel gene fusions can lead to a better comprehension of
cancer progression and development. The emergence of deep sequencing of trancriptome, …